221 filings
Page 9 of 12
CORRESP
42pqa3imz8kv7g y2b6l
22 Jan 18
Correspondence with SEC
12:00am
CORRESP
p6fj51 0bdjjf
22 Jan 18
Correspondence with SEC
12:00am
CORRESP
cr1t5e9243c8kv
22 Jan 18
Correspondence with SEC
12:00am
8-K
ob7tr ufb3kvpp8
18 Jan 18
Athenex Receives Positive Feedback from FDA on the Design of Phase III Clinical Trial for Oraxol
12:00am
UPLOAD
b378djcb1uf296dv3ln
17 Jan 18
Letter from SEC
12:00am
CT ORDER
f3yr4xmd 4d00d4
12 Jan 18
Confidential treatment order
12:00am
8-K
fyk6iqr
5 Jan 18
Entry into a Material Definitive Agreement
12:00am
DRS
oixpv 9gmnbx77
5 Jan 18
Draft registration statement
12:00am
8-K
qqwsfvvrs cx
29 Dec 17
Athenex Receives Promising Innovative Medicine Designation from the United Kingdom MHRA for Oraxol, An Innovative Oral Form of Paclitaxel
12:00am
8-K
s068231mr2kk88y6mn
15 Dec 17
Almirall and Athenex announce strategic partnership for the treatment of actinic keratosis
12:00am
8-K
3bvowhns8 r1k
1 Dec 17
Athenex Announces Planned Retirement of Chief Financial Officer Nick Riehle
12:00am
8-K
9ebzzqm0kk2rkvjq41ue
9 Nov 17
Athenex, Inc. Announces Third Quarter 2017 Results
12:00am
8-K
1xnnk9mmq4fcqv
5 Oct 17
Unregistered Sales of Equity Securities
12:00am
8-K
j5nclik388 wfkr3n
5 Oct 17
Athenex Announces Positive Recommendations from the Drug Safety Monitoring Board to Continue the Oraxol Phase III Program
12:00am
8-K
ch42cj7wh8q2
8 Sep 17
Entry into a Material Definitive Agreement
12:00am
10-Q
uwg5kgw1ngewf1t9x07
14 Aug 17
Quarterly report
12:00am
8-K
zugudqvfz7derb18ngm
14 Aug 17
Athenex, Inc. Announces Second Quarter 2017 Results
12:00am
8-K
mk0ays4sz31
5 Jul 17
Athenex, Inc. Announces Submission of Investigational New Drug Application of Oraxol to Chinese FDA
12:00am